The Health Tech Alliance has summarised below how high-performing products will be identified and selected by the Accelerated Access Collaborative and how support will be offered to such products.
What types of innovations are eligible for support?
Each year, the AAC will identify and support innovations that will have the biggest impact on patient outcomes and NHS services. The AAC will consider a full range of innovations across the development pipeline, including – medicines, therapeutic products, medical technologies, digital products and diagnostic products.
The AAC will take a “flexible and pragmatic approach” to identify game-changing innovations which may not be cost-neutral in year but are assessed by NICE to be both clinically and cost-effective.
Areas of interest for the AAC include:
- evidence of clinical and cost effectiveness
- addressing significant unmet need
- application to large populations or high budget impact
- enabling a novel mode of action or enabling significant changes to the care pathway.
Ensuring your product is visible to the AAC
A system will be established that provides a joined-up approach to existing horizon-scanning activities. This single horizon-scanning system will allow the AAC to identify products without adding further complexity.
Existing infrastructure such as HealthTech Connect will be used. The NIHR Innovation Observatory will be used to identify early stage innovations that are up to 10 years from being publicly available.
Companies are advised to register their products on HealthTech Connect to make sure they are visible to the AAC. Once registered you can check if the AAC have considered it by contacting the AAC Secretariat (AAC@nice.org.uk).
What type of support can a product expect to receive?
Products designated as high potential will receive a tailored package of support, with dedicated case management. The AAC partners and the company will agree this based on their development or accelerated needs.